Abstract：
BACKGROUND: This study evaluated the safety and efficiency of intraperitoneal irrigation chemotherapy with lobaplatin for the treatment of advanced gastric cancer (GC).
METHODS: A total of 56 locally advanced GC patients (experimental group) who received intraoperative intraperitoneal irrigation chemotherapy in addition to undergoing radical D2 surgery were matched 1:1 based on 8 covariates to 56 patients without drug treatment (control group). Clinical data were collected and analyzed.
RESULTS: The two groups were well balanced in basic characteristics and had comparable clinical indices. All patients had similar time to first flatus (2.8 ± 0.3 vs. 2.9 ± 0.3 d, P = 0.076), time to first oral intake (3.5 ± 3.4 vs. 4.1 ± 4.6 d, P = 0.439), and duration of postoperative hospitalization (9.1 ± 3.2 vs. 9.6 ± 4.0 d, P = 0.446). There were no significant differences in postoperative complications including anastomotic and duodenal stump leakage, abdominal and anastomotic bleeding, seroperitoneum, and incision infection between the experimental and control groups (P > 0.05). The rates of chemotherapy-related side effects including allergic reaction, neurotoxicity, diarrhea, and nausea/vomiting were also similar between the two groups, and there were no abnormalities in leukocyte and platelet levels and liver and renal function during the first 5 days after surgery.
CONCLUSIONS: Intraperitoneal irrigation chemotherapy with lobaplatin is safe for patients with advanced gastric cancer.
METHODS: A total of 56 locally advanced GC patients (experimental group) who received intraoperative intraperitoneal irrigation chemotherapy in addition to undergoing radical D2 surgery were matched 1:1 based on 8 covariates to 56 patients without drug treatment (control group). Clinical data were collected and analyzed.
RESULTS: The two groups were well balanced in basic characteristics and had comparable clinical indices. All patients had similar time to first flatus (2.8 ± 0.3 vs. 2.9 ± 0.3 d, P = 0.076), time to first oral intake (3.5 ± 3.4 vs. 4.1 ± 4.6 d, P = 0.439), and duration of postoperative hospitalization (9.1 ± 3.2 vs. 9.6 ± 4.0 d, P = 0.446). There were no significant differences in postoperative complications including anastomotic and duodenal stump leakage, abdominal and anastomotic bleeding, seroperitoneum, and incision infection between the experimental and control groups (P > 0.05). The rates of chemotherapy-related side effects including allergic reaction, neurotoxicity, diarrhea, and nausea/vomiting were also similar between the two groups, and there were no abnormalities in leukocyte and platelet levels and liver and renal function during the first 5 days after surgery.
CONCLUSIONS: Intraperitoneal irrigation chemotherapy with lobaplatin is safe for patients with advanced gastric cancer.
摘要：
背景：这项研究评估了洛铂腹腔灌注化疗治疗晚期胃癌（GC）的安全性和有效性。
方法：共有56例局部晚期GC患者（实验组）在接受D2根治术的同时接受了术中腹腔冲洗化疗，根据8个协变量与56例未接受药物治疗的患者（对照组）进行1:1匹配。收集并分析临床数据。
结果：两组基本特征平衡，临床指标相当。所有患者的首次排气时间相似（2.8±0.3vs.2.9±0.3d,P=0.076),首次口服时间（3.5±3.4vs.4.1±4.6d,P=0.439),术后住院时间（9.1±3.2vs.9.6±4.0d,P=0.446）。术后并发症包括吻合口和十二指肠残端漏无显著差异,腹部和吻合口出血，腹膜,实验组与对照组切口感染差异无统计学意义(P>0.05)。化疗相关副作用的发生率，包括过敏反应，神经毒性，腹泻,恶心/呕吐在两组之间也相似，术后前5天白细胞和血小板水平及肝肾功能均无异常。
结论：洛铂腹腔灌注化疗对晚期胃癌患者是安全的。
方法：共有56例局部晚期GC患者（实验组）在接受D2根治术的同时接受了术中腹腔冲洗化疗，根据8个协变量与56例未接受药物治疗的患者（对照组）进行1:1匹配。收集并分析临床数据。
结果：两组基本特征平衡，临床指标相当。所有患者的首次排气时间相似（2.8±0.3vs.2.9±0.3d,P=0.076),首次口服时间（3.5±3.4vs.4.1±4.6d,P=0.439),术后住院时间（9.1±3.2vs.9.6±4.0d,P=0.446）。术后并发症包括吻合口和十二指肠残端漏无显著差异,腹部和吻合口出血，腹膜,实验组与对照组切口感染差异无统计学意义(P>0.05)。化疗相关副作用的发生率，包括过敏反应，神经毒性，腹泻,恶心/呕吐在两组之间也相似，术后前5天白细胞和血小板水平及肝肾功能均无异常。
结论：洛铂腹腔灌注化疗对晚期胃癌患者是安全的。
